PM
Therapeutic Areas
Carmat Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Aeson® Artificial Heart | End-stage biventricular heart failure (Bridge-to-Transplant) | Pivotal Study (U.S.) |
Leadership Team at Carmat
SP
Stéphane Piat
Chief Executive Officer
DF
Dr. Francesco Nappi
Chief Medical Officer
DC
Dr. Christian Latrémouille
Medical Director & Co-Founder
PA
Prof. Alain Carpentier
Founder, Chief Scientific Officer, Chairman of Scientific Advisory Board
JC
Jean-Michel Creissel
Chief Financial Officer
BG
Benoît Gausseron
Chairman of the Board of Directors